New Delhi, April 28 -- Pharma companies are expected to report healthy revenue growth of 11-13% in the fourth quarter of FY25, driven by strong traction in niche US generic drugs, steady domestic performance in a seasonally weak quarter, and higher sales of a blockbuster cancer drug in the US before its distribution exclusivity ends next year, analysts said.

Uncertainties over US tariffs and the end of the limited competition period for generic Revlimid in the US loom in the months ahead. However, analysts anticipate higher sales of Revlimid to drive growth for US-focused companies such as Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd and Sun Pharmaceutical Industries Ltd in Q4 and the first few quarters of the next fiscal.

"We expe...